Projo Biz Blog

Amgen Inc., the biotechnology company that runs a plant in West Greenwich, said its experimental drug denosumab was more effective than Merck & Co.'s Fosamax at improving women's bone density in a study.

Denosumab, a twice-yearly injection, increased bone density at the hip by 3.5 percent, compared with 2.5 percent for weekly Fosamax pills, according to a one-year study released today at the European Symposium on Calcified Tissue in Barcelona.

Amgen is counting on denosumab, its most advanced drug in development, to offset the sales declines for Aranesp and Epogen, its top-selling anemia medicines linked at high doses to risk of heart attack, stroke and death. The Thousand Oaks, California-based company may generate $3 billion a year in denosumab sales if the drug is approved to treat osteoporosis, analysts say.

Comments

Shirley DeBoer said:

This is very good news for Amgen today. Let's hope it is approved quickly so Fosamax customers can receive the benefits.

Link | May 28, 2008 4:28 PM
Report Abuse

---

Leave a comment

Name:

Email:

URL:  

Remember personal info?

Captcha:

Type the characters you see in the picture above.